TherapeuticsMD, Inc. announced the election of Jules A. Musing, a former senior executive at Johnson & Johnson, to its Board of Directors, effective immediately. Mr. Musing has more than 36-years' experience in the pharmaceutical and biotechnology industry and has been President and Managing Director of Johnson & Johnson subsidiary companies in the United States and Europe; President of Ares Serono, Inc. in the United States; and Executive Vice President of Ares Serono in North and Latin America. He also has been on the Board of Directors of Johnson & Johnson companies in Germany, France, Italy and the UK and has been a member of the Management Board of Ortho Biotech (a Johnson & Johnson biotechnology company) in the United States and Europe.

TherapeuticsMD, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the quarter, the company reported net revenues of $1,537,195 against $721,692 for the same period a year ago. Operating loss was $4,942,891 against $2,868,021 for the same period a year ago. Loss before taxes was $6,375,653 against $13,289,603 for the same period a year ago. Net loss was $6,375,653 or $0.06 per basic and diluted share against $13,289,603 or $0.16 per basic and diluted share for the same period a year ago. Net cash flow used in operating activities $3,508,682 against $2,451,985 for the same period a year ago. Purchase of plant, property and equipment was $22,905 against $32,386 for the same period a year ago.

TherapeuticsMD, Inc. filed its 10-K on Mar 12, 2013 for the period ending Dec 31, 2012. In this report its auditor, Rosenberg Rich Baker Berman & Company, gave an unqualified opinion expressing doubt that the company can continue as a going concern.